1. |
Yin P, Wang HD, Vos T, et al. A subnational analysis of mortality and prevalence of COPD in China from 1990 to 2013: findings from the global burden of disease study 2013. Chest, 2016, 150(6): 1269-1280.
|
2. |
Wang M, Zhang Y, Xu M, et al. Roles of TRPA1 and TRPV1 in cigarette smoke-induced airway epithelial cell injury model. Free Radic Biol Med, 2019, 134: 229-238.
|
3. |
Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management and prevention Of Chronic Obstructive Pulmonary Disease. (2017 REPORT). http://www.goldcopd.org.
|
4. |
Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2012, 185(1): 44-52.
|
5. |
谢晓然, 鲍文华, 杨泽. 肿瘤坏死因子-α 基因多态性与黑龙江省东部地区慢性阻塞性肺疾病人群易感性的研究. 中国呼吸与危重监护杂志, 2019, 18(3): 217-223.
|
6. |
何子凡, 高岩, 王晓玲, 等. NLRP3 炎性小体在慢性阻塞性肺疾病患者机体炎症反应中作用的研究. 中国呼吸与危重监护杂志, 2018, 17(2): 119-123.
|
7. |
Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One, 2012, 7(5): e37483.
|
8. |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南 (2013 年修订版). 中华结核和呼吸杂志, 2013, 36(4): 255-264.
|
9. |
Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation, 2006, 113(19): 2335-2362.
|
10. |
Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med, 2010, 182(5): 598-604.
|
11. |
赵春柳, 黄靓雯, 张利, 等. 慢性阻塞性肺疾病急性加重住院患者呼吸道病毒感染与炎症细胞因子的相关性. 中华结核和呼吸杂志, 2018, 41(12): 942-948.
|
12. |
Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature, 2005, 437(7061): 1032-1037.
|
13. |
Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet, 2011, 12(1): 56-68.
|
14. |
Sin DD, Man SFP, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Respir Crit Care Med, 2008, 177(11): 1207-1214.
|
15. |
Di Stefano A, Coccini T, Roda E, et al. Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema. Int J Chron Obstruct Pulmon Dis, 2018, 13: 1691-1700.
|
16. |
Vitenberga Z, Pilmane M, BabjoniŠeva A. The evaluation of inflammatory, anti-inflammatory and regulatory factors contributing to the pathogenesis of COPD in airways. Pathol Res Pract, 2019, 215(1): 97-105.
|
17. |
Ryrsø CK, Thaning P, Siebenmann C, et al. Effect of endurance versus resistance training on local muscle and systemic inflammation and oxidative stress in COPD. Scand J Med Sci Sports, 2018, 28(11): 2339-2348.
|
18. |
Verhamme FM, Bracke KR, Amatngalim GD, et al. Role of activin-A in cigarette smoke-induced inflammation and COPD. Eur Respir J, 2014, 43(4): 1028-1041.
|
19. |
Tania NP, Schmidt M, Gosens R. Activin-A: active in inflammation in COPD. Eur Respir J, 2014, 43(4): 954-955.
|
20. |
Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature, 2006, 444(7121): 875-880.
|
21. |
Fuller-Thomson E, Howden KEN, Fuller-Thomson LR, et al. A strong graded relationship between level of obesity and COPD: findings from a national population-based study of lifelong nonsmokers, J Obes. 2018, 2018: 6149263.
|
22. |
Janssen DJ, Müllerova H, Agusti A, et al. Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. Respir Med, 2014, 108(11): 1647-1654.
|